Quantcast

Low dose Isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: a case series.

Research paper by Dharmendra Dineshchandra DD Dave, Ayman A Abdelmaksoud

Indexed on: 22 Jan '19Published on: 22 Jan '19Published in: Dermatologic Therapy



Abstract

Warts constitute the most frequently observed dermatological manifestations of human papillomavirus (HPV). Although an extensive range of treatments exists for local warts, there is no specific therapy based on high-quality evidence of notable treatment success or high cure rate, or minimal adverse effects. Recalcitrant warts are, therefore, a common therapeutic problem. This case series refer to 14 immunocompetent patients with recalcitrant warts, who experienced full resolution of their warty lesions when treated with addition of low dose isotretinoin, in a dose of 0.1-0.2 mg/kg/day, for a 3-month course, with no significant adverse effects. Long-term remission was noted for up to 3 years with no signs of active lesions. Low dose isotretinoin should be in the priority of the treatment options of recalcitrant warts, alone or in-combination. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.